Market Cap 21.92B
Revenue (ttm) 13.01B
Net Income (ttm) 746.00M
EPS (ttm) N/A
PE Ratio 17.78
Forward PE 16.32
Profit Margin 5.73%
Debt to Equity Ratio 0.67
Volume 664,003
Avg Vol 790,576
Day's Range N/A - N/A
Shares Out 83.70M
Stochastic %K 67%
Beta 0.81
Analysts Strong Sell
Price Target $278.53

Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 336 229 1127
Address:
358 South Main Street, Burlington, United States
Estimize
Estimize Jun. 23 at 12:03 PM
Wall St is expecting 4.18 EPS for $LH Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/lh?chart=historical&metric_name=eps&utm_conten
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 1:10 PM
$LH up 25.6% over the past year, outperforming the industry's 16.2% fall and S&P 500's 9.1% gain — what's driving this rally? 🚀 Labcorp's strategic acquisitions, enhanced neurodegenerative testing, and LaunchPad savings initiatives are fueling growth. Plus, their solid cash position and no short-term debt add financial strength. Discover Labcorp's growth strategy here 👉 https://www.zacks.com/commentary/2510266/labcorp-stock-climbs-256-this-year-whats-driving-the-surge?cid=sm-stocktwits-2-2510266-body&ADID=SYND_STOCKTWITS_TWEET_2_2510266_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 11:34 AM
$LH up 25.6% YTD — what’s fueling the rally? Specialty testing is gaining momentum, recent acquisitions are clicking, and financials are holding strong. See what’s behind the move 👉 https://www.zacks.com/stock/news/2510266/labcorp-stock-climbs-256-this-year-whats-driving-the-surge?cid=sm-stocktwits-2-2510266-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2510266_TEASER
0 · Reply
MHM7700
MHM7700 Jun. 12 at 1:49 PM
$TSLA – Attempting Recovery After Breakdown Key Resistance: $325.08 → $326.48 → $329.00 Support Levels: $321.54 → $318.13 → $315.25 Technical Summary: • Breakdown from lower high ($LH) structure led to extended selling into $318. • EMAs are bearishly stacked; price below VWAP and anchored supply zone. • Volume surge on morning bounce into $323.40, but struggling under supply. • RSI still under neutral zone. Structure Note: Oversold bounce from $318 zone. Sellers stepped back in under $325.08. Now testing supply-to-neutral transition. Bullish Plan: Above $323.40 with volume → Reclaim $325.08 and squeeze to $326.48 Over $326.48 → Full retrace to $329 possible Bearish Plan: Failure at $323.40 → Rejection zone opens path toward $321.54 and $318 Under $318 = trigger short toward $315.25 on trend continuation Needs strong reclaim of $325.08 to flip momentum. Otherwise, sellers remain in control below $323.
0 · Reply
JarvisFlow
JarvisFlow Jun. 11 at 2:49 PM
Morgan Stanley has updated their rating for Labcorp Hldgs ( $LH ) to Overweight with a price target of 283.
0 · Reply
Estimize
Estimize Jun. 9 at 12:03 PM
Wall St is expecting 4.18 EPS for $LH Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/lh?chart=historical&metric_name=eps&utm_conten
0 · Reply
ZacksResearch
ZacksResearch Jun. 4 at 2:00 PM
$LH up 26.5% in a year — what's driving this outperformance? 🚀 🔬 Focus on high-growth testing areas like oncology and neurology 🤝 Strategic acquisitions and partnerships fueling expansion 💰 Strong financials with no short-term debt at the end of Q1 2025 and robust buyback strategy Discover why Labcorp is a Zacks Rank #2 stock here 👉 https://www.zacks.com/commentary/2484199/should-you-continue-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2484199-body&ADID=SYND_STOCKTWITS_TWEET_2_2484199_BODY
0 · Reply
swingingtech
swingingtech Jun. 4 at 1:48 PM
$LH https://wallstreetwaves.com/is-labcorp-stock-a-worthy-hold-for-your-investment-portfolio/
0 · Reply
ZacksResearch
ZacksResearch Jun. 4 at 11:37 AM
$LH looks strong — but is it strong enough? The company’s growth focus and solid financials are encouraging, but rising competition and macro headwinds raise real questions. Full breakdown here 👉 https://www.zacks.com/stock/news/2484199/should-you-continue-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2484199-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2484199_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 2 at 3:33 PM
$LH expands oncology portfolio — bullish for precision medicine! 🚀 Labcorp's new tests for solid tumors & hematologic malignancies aim to accelerate trials and diagnostics, contributing to the broader precision oncology market's projected growth. Discover why LH is poised for growth here 👉 https://www.zacks.com/commentary/2480345/lh-stock-rises-following-the-expansion-of-precision-oncology-portfolio?cid=sm-stocktwits-2-2480345-body&ADID=SYND_STOCKTWITS_TWEET_2_2480345_BODY
0 · Reply
Latest News on LH
Labcorp to Webcast Its Annual Meeting of Shareholders May 15

May 8, 2025, 4:15 PM EDT - 6 weeks ago

Labcorp to Webcast Its Annual Meeting of Shareholders May 15


Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:21 PM EDT - 2 months ago

Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript


Labcorp Announces 2025 First Quarter Results

Apr 29, 2025, 6:50 AM EDT - 2 months ago

Labcorp Announces 2025 First Quarter Results


Labcorp Declares Quarterly Dividend

Apr 10, 2025, 6:50 AM EDT - 2 months ago

Labcorp Declares Quarterly Dividend


Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 3:42 PM EST - 4 months ago

Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript


Labcorp Announces 2024 Fourth Quarter and Full Year Results

Feb 6, 2025, 6:50 AM EST - 4 months ago

Labcorp Announces 2024 Fourth Quarter and Full Year Results


LABCORP DECLARES QUARTERLY DIVIDEND

Jan 8, 2025, 6:02 PM EST - 5 months ago

LABCORP DECLARES QUARTERLY DIVIDEND


Labcorp CFO Glenn Eisenberg Announces Plans to Retire

Nov 19, 2024, 7:00 AM EST - 7 months ago

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

ONC


Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 2:00 PM EDT - 8 months ago

Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript


Labcorp beats quarterly estimates on diagnostic test demand

Oct 24, 2024, 7:10 AM EDT - 8 months ago

Labcorp beats quarterly estimates on diagnostic test demand


Labcorp Announces 2024 Third Quarter Results

Oct 24, 2024, 6:50 AM EDT - 8 months ago

Labcorp Announces 2024 Third Quarter Results


CommonWell Health Alliance Welcomes Labcorp as Newest Member

Sep 18, 2024, 9:00 AM EDT - 9 months ago

CommonWell Health Alliance Welcomes Labcorp as Newest Member


Labcorp to Speak at the Baird 2024 Global Healthcare Conference

Sep 3, 2024, 4:09 PM EDT - 10 months ago

Labcorp to Speak at the Baird 2024 Global Healthcare Conference


Labcorp says it could ramp up mpox testing capacity

Aug 26, 2024, 6:22 AM EDT - 10 months ago

Labcorp says it could ramp up mpox testing capacity


Labcorp Finalizes Acquisition of Select Assets of Invitae

Aug 5, 2024, 7:00 AM EDT - 11 months ago

Labcorp Finalizes Acquisition of Select Assets of Invitae

NVTAQ


Labcorp Holdings Inc (LH) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 3:15 PM EDT - 11 months ago

Labcorp Holdings Inc (LH) Q2 2024 Earnings Call Transcript


Estimize
Estimize Jun. 23 at 12:03 PM
Wall St is expecting 4.18 EPS for $LH Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/lh?chart=historical&metric_name=eps&utm_conten
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 1:10 PM
$LH up 25.6% over the past year, outperforming the industry's 16.2% fall and S&P 500's 9.1% gain — what's driving this rally? 🚀 Labcorp's strategic acquisitions, enhanced neurodegenerative testing, and LaunchPad savings initiatives are fueling growth. Plus, their solid cash position and no short-term debt add financial strength. Discover Labcorp's growth strategy here 👉 https://www.zacks.com/commentary/2510266/labcorp-stock-climbs-256-this-year-whats-driving-the-surge?cid=sm-stocktwits-2-2510266-body&ADID=SYND_STOCKTWITS_TWEET_2_2510266_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 11:34 AM
$LH up 25.6% YTD — what’s fueling the rally? Specialty testing is gaining momentum, recent acquisitions are clicking, and financials are holding strong. See what’s behind the move 👉 https://www.zacks.com/stock/news/2510266/labcorp-stock-climbs-256-this-year-whats-driving-the-surge?cid=sm-stocktwits-2-2510266-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2510266_TEASER
0 · Reply
MHM7700
MHM7700 Jun. 12 at 1:49 PM
$TSLA – Attempting Recovery After Breakdown Key Resistance: $325.08 → $326.48 → $329.00 Support Levels: $321.54 → $318.13 → $315.25 Technical Summary: • Breakdown from lower high ($LH) structure led to extended selling into $318. • EMAs are bearishly stacked; price below VWAP and anchored supply zone. • Volume surge on morning bounce into $323.40, but struggling under supply. • RSI still under neutral zone. Structure Note: Oversold bounce from $318 zone. Sellers stepped back in under $325.08. Now testing supply-to-neutral transition. Bullish Plan: Above $323.40 with volume → Reclaim $325.08 and squeeze to $326.48 Over $326.48 → Full retrace to $329 possible Bearish Plan: Failure at $323.40 → Rejection zone opens path toward $321.54 and $318 Under $318 = trigger short toward $315.25 on trend continuation Needs strong reclaim of $325.08 to flip momentum. Otherwise, sellers remain in control below $323.
0 · Reply
JarvisFlow
JarvisFlow Jun. 11 at 2:49 PM
Morgan Stanley has updated their rating for Labcorp Hldgs ( $LH ) to Overweight with a price target of 283.
0 · Reply
Estimize
Estimize Jun. 9 at 12:03 PM
Wall St is expecting 4.18 EPS for $LH Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/lh?chart=historical&metric_name=eps&utm_conten
0 · Reply
ZacksResearch
ZacksResearch Jun. 4 at 2:00 PM
$LH up 26.5% in a year — what's driving this outperformance? 🚀 🔬 Focus on high-growth testing areas like oncology and neurology 🤝 Strategic acquisitions and partnerships fueling expansion 💰 Strong financials with no short-term debt at the end of Q1 2025 and robust buyback strategy Discover why Labcorp is a Zacks Rank #2 stock here 👉 https://www.zacks.com/commentary/2484199/should-you-continue-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2484199-body&ADID=SYND_STOCKTWITS_TWEET_2_2484199_BODY
0 · Reply
swingingtech
swingingtech Jun. 4 at 1:48 PM
$LH https://wallstreetwaves.com/is-labcorp-stock-a-worthy-hold-for-your-investment-portfolio/
0 · Reply
ZacksResearch
ZacksResearch Jun. 4 at 11:37 AM
$LH looks strong — but is it strong enough? The company’s growth focus and solid financials are encouraging, but rising competition and macro headwinds raise real questions. Full breakdown here 👉 https://www.zacks.com/stock/news/2484199/should-you-continue-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2484199-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2484199_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 2 at 3:33 PM
$LH expands oncology portfolio — bullish for precision medicine! 🚀 Labcorp's new tests for solid tumors & hematologic malignancies aim to accelerate trials and diagnostics, contributing to the broader precision oncology market's projected growth. Discover why LH is poised for growth here 👉 https://www.zacks.com/commentary/2480345/lh-stock-rises-following-the-expansion-of-precision-oncology-portfolio?cid=sm-stocktwits-2-2480345-body&ADID=SYND_STOCKTWITS_TWEET_2_2480345_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 2 at 1:21 PM
$LH stock is making moves after a major precision oncology boost! Labcorp just rolled out new cancer tests and a global diagnostic tool — this could be a game-changer for its growth prospects. See why this could be bullish for LH 👉 https://www.zacks.com/stock/news/2480345/lh-stock-rises-following-the-expansion-of-precision-oncology-portfolio?cid=sm-stocktwits-2-2480345-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2480345_TEASER
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:38 AM
$LH Labcorp expands precision oncology portfolio Labcorp announced the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma solutions designed to accelerate clinical trials and companion diagnostic development.
0 · Reply
DonCorleone77
DonCorleone77 May. 23 at 10:34 PM
$LH Labcorp awarded $117.03M Army contract modification Labcorp was awarded a $117.03M modification to a contract for clinical reference laboratory testing services. Bids were solicited via the internet with two received. Work locations and funding will be determined with each order, with an estimated completion date of Dec. 31, 2025. U.S. Army Health Contracting Activity, San Antonio, Texas, is the contracting activity.
0 · Reply
IN0V8
IN0V8 May. 21 at 5:15 PM
$LH Buy Mizuho raises target price to $274 from $264
0 · Reply
kylehardy15
kylehardy15 May. 15 at 2:11 PM
$LUCD $BSX $MDT $STE $LH STERIS purchased truFreeze a few years back which treats esophageal cancer.
2 · Reply
JarvisFlow
JarvisFlow May. 12 at 6:04 PM
Truist Securities updates rating for Labcorp Hldgs ( $LH ) to Buy, target set at 274 → 290.
0 · Reply
IN0V8
IN0V8 May. 12 at 5:09 PM
$LH bUY Truist Securities raises target price to $290 from $274
0 · Reply
Armonica423
Armonica423 May. 10 at 10:15 PM
$LH Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
IN0V8
IN0V8 May. 6 at 6:43 PM
$LH Buying Opportunity Piper Sandler raises target price to $280 from $260
0 · Reply
JarvisFlow
JarvisFlow May. 6 at 4:15 PM
Piper Sandler updates rating for Labcorp Hldgs ( $LH ) to Neutral, target set at 260 → 280.
0 · Reply
xx007xx
xx007xx May. 2 at 10:56 AM
$LUCD $BSX $MDT $STE $LH Yeah, I guess none of these organizations have any form of interest in the esophageal disease space. But what do I know? Just a quick google search of diagnostic & therapeutics for the esophagus. 🙈😉🙄
1 · Reply
JarvisFlow
JarvisFlow Apr. 30 at 10:30 PM
Barclays has updated their rating for Labcorp Hldgs ( $LH ) to Equal-Weight with a price target of 250.
0 · Reply